Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells

Oral Oncology

Volumn 44, Issue 4, 2008, Pages 361-368

  Iwase, Masayasu ^a   Takaoka, Sayaka ^a   Uchida, Makiko ^a   Yoshiba, Sayaka ^a   Kondo, Gen ^a   Watanabe, Hitoshi ^a   Ohashi, Masaru ^a   Nagumo, Masao ^a  

^a SHOWA UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

Apoptosis; c FLIP; EGFR inhibitor; Fas; Squamous cell carcinoma

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CASPASE 3 INHIBITOR; CASPASE 8; CASPASE 8 INHIBITOR; CASPASE 9 INHIBITOR; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; PROCASPASE 8; PROTEIN BID; PROTEIN KINASE B; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; ENZYME INHIBITORS; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; MOUTH NEOPLASMS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 40749106939     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.04.006     Document Type: Article

References (54)

1. Forastiere A.A., Koch W., Trotti A., and Sidransky D. Head and neck cancer. N Engl J Med 345 (2002) 1890-1900
2. Jefferies S., and Foulkes W.D. Genetic mechanisms in squamous cell carcinoma. Oral Oncol 37 (2001) 115-126
3. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20 (2002) 1S-13S
4. Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29 (2002) S3-S9
5. Shin D.M., Ro J.Y., Hong W.K., and Hittelman W.N. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54 (1994) 3153-3159
6. Grandis J.R., Mclhem M.F., Barnes E.L., and Tweardy D.J. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78 (1996) 1284-1292
7. Kitagawa Y., Ueda M., Ando N., Ozawa S., Shimizu N., and Kitajima M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2 (1996) 909-914
8. Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
9. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
10. Herbst R.S., and Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94 (2002) 1593-1611
11. Cohen E.E., Rosen F., Stadler W.M., Recant W., Stenson K., Huo D., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 (2003) 1980-1987
12. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., and Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
13. Magne N., Fischel J.L., Tiffon C., Formento P., Dubrenil A., Renee N., et al. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br J Cancer 89 (2003) 585-592
14. Herbst R.S., Arquette M., Shin D.M., Dicke K., Vokes E.E., Azarnia N., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5578-5587
15. Burtness B., Goldwasser M.A., Flood W., Mattar B., and Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
16. Pfister D.G., Su Y.B., Kraus D.H., Wolden S.L., Lis E., Aliff T.B., et al. Concurrent cetuximab, cisplatin, and combination boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24 (2006) 1072-1078
17. Chang G.C., Hsu S.L., Tsai J.R., Liang F.P., Lin S.Y., Sheu G.T., et al. Molecular mechanisms of ZD 1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol 68 (2004) 1453-1464
18. Piechoki M.P., Yoo G.H., Dibbley S.K., Amiad E.H., and Lonardo F. Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int J Cancer 119 (2006) 441-454
19. Bremer E., Samblonius D.F., van Genne L., Diikstra M.H., Kroesen B.J., de Leji L.F., et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv: sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 280 (2005) 10025-10033
20. Jarpe M.B., Widmann C., Knall C., Schlesinger T.K., Gibson S., Yujiri T., et al. Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene 17 (1998) 3261-3270
21. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
22. Peter M.E., and Krammer P.H. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 10 (1998) 545-551
23. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., et al. Two CD95 (APO-1/Fas) signaling pathway. EMBO J 17 (1998) 1675-1687
24. Gratas C., Tohma Y., Bamas C., Taniere P., Hainaut P., and Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 58 (1998) 2057-2062
25. Moers C., Warskulat U., Muschen M., Even J., Niederacher D., Joeien R., et al. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-γ and cisplatin. Int J Cancer 80 (1999) 564-572
26. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 (1998) 1312-1316
27. Scaffidi C., Schmitz I., Zha J., Korsmeyer S.J., Krammer P.H., and Peter M.E. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 274 (1999) 22532-22538
28. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
29. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
30. Krueger A., Baumann S., Krammer P.H., and Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21 (2001) 8247-8254
31. Scaffidi C., Schmitz I., Krammer P.H., and Peter M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274 (1999) 1541-1548
32. Ryu B.K., Lee M.G., Chi S.G., Kim Y.W., and Park J.H. Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 194 (2001) 15-19
33. Rippo M.R., Moretti S., Vescovi S., Tomasetti M., Orecchia S., Amici G., et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 14 (2004) 7753-7760
34. Iwase M., Watanabe W., Kondo G., Ohashi M., and Nagumo M. Enhanced susceptibility of oral squamous cell carcinoma cell lines to Fas-mediated apoptosis by cisplatin and 5-fluorouracil. Int J Cancer 106 (2003) 619-625
35. Kondo G., Iwase M., Watanabe H., Uchida M., Takaoka S., Ohashi M., et al. Enhancement of susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells by phosphatidylinositol 3-kinase inhibitor. Oral Oncol 42 (2006) 745-752
36. Huang S., Armstrong E.A., Benavente S., Chinnaivan P., and Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64 (2004) 5355-5362
37. Micheau O., Solary E., Hammann A., Martin F., and Dimanche-Boitrel M.T. Sensitization of cancer cells treated with cytotoxic drugs Fas-mediated cytotoxicity. J Natl Cancer Inst 89 (1997) 783-789
38. Ferreira C.G., Span S.W., Peters G.J., Kruyt F.A.K., and Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 60 (2000) 7133-7141
39. Bancroft C.C., Chen Z., Yeh J., Sunwoo J.B., Yeh N.T., Jackson S., et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99 (2002) 538-548
40. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 13 (1999) 2905-2927
41. Chakravarti A., Loeffler J.S., and Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62 (2002) 200-207
42. Janmaat M.L., Kruyt F.A., Rodriguez J.A., and Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase and Akt kinase pathway. Clin Cancer Res 9 (2003) 2316-2326
43. Musallam L., Ethier C., Haddad P.S., and Bilodeau M. EGF mediates protection against Fas-induced apoptosis by depleting and oxidizing intracellular GHS stocks. J Cell Physiol 198 (2004) 62-72
44. Musallam L., Ethier C., Haddad P.S., and Bilodeau M. Role of EGF receptor tyrosine kinase activity in antiapoptotic effect of EGF on mouse hepatocytes. Am J Physiol Gastrointest Liver Physiol 280 (2001) G1360-G1369
45. Golubovskaya V., Beviglia L., Xu L.H., Earp H.S., Craven R., and Cance W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 277 (2002) 38978-38987
46. Häusler P., Papoff G., Eramo A., Reif K., Cantrell D.A., and Rubert G. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. Eur J Immunol 28 (1998) 57-69
47. Kinoshita H., Yoshikawa H., Shiiki K., Hamada Y., Nakajima Y., and Tasaka K. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 88 (2000) 986-991
48. Steinbach J.P., Eisnmann C., Klumpp A., and Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem Biophys Res Commun 321 (2004) 524-530
49. Qiao L., Studer E., Leach K., McKinstry R., Gupta S., Decker S., et al. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes; inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell 12 (2001) 2629-2645
50. Panka D.J., Mano T., Suhara T., Walsh K., and Mier J.W. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276 (2001) 6893-6896
51. Nam S.Y., Jung G.A., Hur G.C., Chung H.Y., Kim W.H., Seol D.W., et al. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94 (2003) 1066-1073
52. Mitsiades C.S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., Chauhan D., et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21 (2002) 5673-5683
53. Siegmund D., Hadwiger P., Pfizenmaier K., Vornlocher H.P., and Wajant H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitizes tumor cells for TRAIL-induced apoptosis. Mol Med 8 (2002) 725-732
54. Medema J.P., de Jong J., van Hall T., Melief C.J.M., and Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 190 (1999) 1033-1038